logo
NHS gets an extra £29billion a year but waiting list targets may STILL be missed, health chiefs say

NHS gets an extra £29billion a year but waiting list targets may STILL be missed, health chiefs say

Daily Mail​a day ago

The NHS is unlikely to hit waiting time targets despite getting an extra £29billion a year in the Spending Review, health chiefs said last night.
Economists described the real-terms rise as 'substantial', with the health service budget now equal to the entire annual income of Portugal.
But patients were yesterday told to brace for cuts to services, with much of the extra cash set to be swallowed up by inflation-busting pay rises and higher drugs costs.
Rachel Reeves told the Commons she is making a 'record cash investment' in the NHS, worth an extra 3 per cent a year in real terms.
The Chancellor insisted this would lead to 'more appointments, more doctors and more scanners' as Labour seeks to deliver on its manifesto promise to get the NHS 'back on its feet'.
But the settlement received a lukewarm response from NHS bosses, who said they would need even more money if the Government is to achieve its aim of treating 92 per cent of patients within 18 weeks of a GP referral by the end of this Parliament.
Matthew Taylor, of the NHS Confederation, which represents health organisations, said: 'Difficult decisions will still need to be made as this additional £29billion won't be enough to cover increasing costs of new treatments, with staff pay likely to account for a large proportion of it.
'On its own, this won't guarantee that waiting time targets are met.'
Sir Jim Mackey, chief executive of NHS England, told the NHS ConfedExpo conference in Manchester that the health service has done 'really well relative to other parts of the public service'.
But he added: 'We all know it's never enough because of the scale of advancement, all the ambition, the day-to-day cost pressures... but I think everyone's starting to accept and understand we've got what the country can afford to give us.
'We really need to get better value for that money – it is broadly the equivalent of the GDP of Portugal, so it's a huge amount.'
Government documents accompanying the Spending Review show that, on average, from 2023/24 to 2028/29, the NHS in England will receive 3 per cent real-terms growth in day-to-day spending, equivalent to a £29billion increase in annual budgets.
The figures suggest Department of Health and Social Care spending will rise 2.8 per cent – less than the average 3.6 per cent seen in recent years.
Paul Johnson, director of the Institute for Fiscal Studies, said the NHS was the 'biggest winner' in the Spending Review and described the Department of Health as a 'behemoth'.
But he added: 'Even here, one has to wonder whether this will be enough. Aiming to get back to meeting the NHS 18-week target for hospital waiting times within this Parliament is enormously ambitious – an NHS funding settlement below the long-run average might not measure up.'
Sarah Woolnough, of health think-tank the King's Fund, said: 'It is hard to see how all the things she [Ms Reeves] mentions – faster ambulance times, more GP appointments and adequate mental health services and more – can be met on this settlement alone.
'Particularly when large parts of this funding will be absorbed by existing rising costs, such as the higher cost of medicines... and staff pay deals.'
However, she said the upcoming ten-year plan could lead to better, more efficient NHS services.
According to spending review documents, the Government expects the NHS to deliver 2 per cent productivity growth each year, 'unlocking £17 billion savings over three years' to reinvest and improve patient care.
Sally Gainsbury, at the Nuffield Trust health think-tank, said: 'Compared to settlements for other departments... the NHS deal looks generous.
'But seen in the context of all the promises made by the Government – to drive down waiting lists, shift care closer to home, rapidly improve tech – and the commitments to meet staff pay demands and rising costs of drugs, today's settlement soon melts away.
'With capital funding staying flat in real terms for the rest of the spending review period, it will be difficult for the NHS to invest in the technology and facility upgrades it needs to meet the Government's ambitious productivity targets.'
The Government said it will also invest up to £10 billion in NHS technology and digital transformation by 2028/29, plus £6 billion to speed up tests and treatments.
Scanners, ambulances and urgent treatment centres are among things the additional cash – part of the overall £29 billion – will pay for, with the aim of providing up to 4 million more tests and procedures in the next five years.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Parents whose sons are losing ability to walk face ‘nightmare' battle with NHS
Parents whose sons are losing ability to walk face ‘nightmare' battle with NHS

Western Telegraph

time37 minutes ago

  • Western Telegraph

Parents whose sons are losing ability to walk face ‘nightmare' battle with NHS

The medicine givinostat can slow progress of Duchenne muscular dystrophy – keeping children on their feet for longer – and is being offered for free by a drug firm while it goes through the process of NHS approval. However, only some NHS trusts across the UK, and few in England, are giving the drug despite it being part of an early access programme since November. Families are now facing a 'cruel' postcode lottery over who gets the medicine and are in a race against time, according to the charity Duchenne UK. Some NHS trusts are refusing to supply the drug while others delay it by drawing up lists of who they think should get it first. NHS trusts say they need to pay for monitoring the drug – around £1,900 per year per patient – out of their own budget. In desperation, parents have met with Health Secretary Wes Streeting to try and speed up access. According to the Government, it is up to individual NHS trusts to decide whether to provide the drug. Duchenne UK is supporting families in their fight for givinostat, including Rosie and Pete Day, an investment manager, and their 10-year-old son Jasper, from Horsham, West Sussex. The Day family have twins Jasper and Arabella, aged 10, and two older daughters. Jasper enjoys a range of hobbies (Family handout/PA) Both Jasper and Arabella have Duchenne, with Arabella a carrier of the genetic disorder and Jasper the most affected, as the condition mostly affects boys. The drug, developed by ITF Pharma UK, is only being given under the early access programme to children who are still able to walk. Mrs Day told the PA news agency: 'We try and live in the moment and, in this moment, there's an opportunity to make a massive change to Jasper. 'We're not going to cure it, but this drug gives him the best chance of having the early life that he wants to have and what every parent wants to give their child. 'It's so close – and yet we're stuck. 'We're stuck in this process where there's something in reaching distance that could make a huge difference to keep him walking, keep him active, keep him with his siblings in the garden, keep him walking up the stairs, all of those things, and it just feels that we can't quite get there. 'We're on the finishing line to get something that will make a difference and we can't quite get there because of the system we're in. 'The drug is not going to cure it, but it will give him the childhood you would wish to give your child – to keep them playing football, coming on dog walks, being able to walk up the stairs, playing the French horn, all of those things that you dream your child is going to get to do. 'We can't give it because it we're stuck, even though it's free and it's there – we can't give it. 'It feels like a nightmare, because you know that the doctors want to give it, but when it comes to getting the drug in his mouth and seeing what it would do, we're stuck. 'It's a lottery, basically, depending on where you are in the country … and within NHS trusts themselves.' Jasper is under the care of the Evelina London Children's Hospital, which is only now starting to contact patients and is drawing up a priority list for who gets the drug first. 'Every day that passes by is a day that we can see Jasper decline and see him struggling with his muscles,' Mrs Day said. 'Two weeks ago, he asked me, 'When will I get the drug, mummy?' 'We're stuck in a situation over who's going to make those decisions regarding who gets the drug – of whether Jasper gets it or another boy. 'For every boy it's heartbreaking, because someone ultimately is not going to get the drug at that moment based on the current criteria.' She added: 'If Jasper stops walking, we're not going to get that back. 'Every day matters. Six months ago, Jasper could walk up and down the stairs easily. He can't do that now and Pete has to push him up the stairs every night. 'Yet we can't give him something that is as simple as two spoons full of medicine and a blood test, and a little bit of maybe resource looking at the blood test results – that is what is standing in our way.' Mrs Day said it was unclear how the Evelina is 'going to make a fair choice' because knowing who will lose mobility is not an exact science. Mr Day said the process is 'hugely subjective' because there is no linear decline in the condition and the decisions made by NHS trusts could end up being 'completely wrong'. According to Duchene UK, boys whose condition is getting worse risk falling off the list entirely while waiting for the drug. Around 500 boys in the UK are eligible for givinostat, which can be taken at home like Calpol, with hospitals then doing follow-up blood tests of around eight in the first year, followed by twice a year thereafter. Children may also need an ECG, though these are already part of routine Duchenne monitoring. Emily Reuben and Alex Johnson, founders of Duchenne UK, said: 'As time ticks by, more boys are losing out on their chance to access givinostat. 'This is a simple treatment, which can be easily managed at home, and requires uncomplicated blood tests to monitor. It's free to the NHS and could offer real hope for patients and their families. 'The delays are cruel and the postcode lottery is unjustifiable. We are calling on the NHS to urgently make this available to both ambulant (walking) and non-ambulant boys.' To date, all health boards in Scotland are rolling out the drug, alongside those in Swansea and Cardiff. Leicester Royal Infirmary was the first trust in England to give the drug, but the Evelina has not yet, and neither have trusts in Manchester, Liverpool and Newcastle. Great Ormond Street Hospital is working to supply the drug. A spokesman for the Evelina said: 'We have begun contacting families of all existing Evelina London patients who may be eligible for givinostat and are working to set up appointments in the next few months. 'Our clinical team are working through our patient lists and are currently prioritising children who need the treatment most urgently, or are at a higher risk of losing movement (ambulation) soon.' An NHS spokesman said: 'The first National Institute for Health and Care Excellence (Nice) committee meeting to consider this treatment is scheduled to be held in July 2025, and if manufacturer ITF Pharma can offer a cost-effective price to enable Nice to recommend its use, the NHS will be ready to work with the company to explore fast-tracking access for patients. 'NHS England has published guidance on manufacturer-led early access schemes, which require trusts to cover substantial costs and find additional clinical resources to administer new treatments, and we understand a number of trusts across the country are preparing to offer givinostat via such a scheme.'

‘Trojan horse' treatment given green light for NHS use
‘Trojan horse' treatment given green light for NHS use

Western Telegraph

time38 minutes ago

  • Western Telegraph

‘Trojan horse' treatment given green light for NHS use

The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest. It is estimated that around 1,500 patients a year with multiple myeloma – an incurable cancer of the bone marrow – will benefit from the treatment. Paul Silvester received his treatment at the Royal Hallamshire Hospital in Sheffield (handout/PA) It comes after the National Institute for Health and Care Excellence (Nice) approved belantamab mafodotin, also known as Blenrep and made by GlaxoSmithKline, for NHS use. NHS England said that it is the first health system in the world to roll out the treatment. Officials said that the drug can now be offered to patients whose cancer has progressed or not responded to another first-line treatment. The treatment, which is given as an infusion every three weeks along with other cancer drugs, is a type of antibody drug which targets and attaches to cancer cells. It has been dubbed a 'Trojan horse' treatment because it works by being taken into a cancer cell, before releasing a high concentration of a lethal molecule to destroy the cell from inside. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' Professor Peter Johnson, NHS England's national clinical director for cancer, said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' 🚨 Do you know the key symptoms of #myeloma? 🚨 Help us spread the word by sharing this post! Early diagnosis makes all the difference. If something feels off, don't wait – talk to your GP!#BloodCancerAwarenessMonth @MyelomaUK — DKMS UK | We Delete Blood Cancer (@DKMS_uk) September 6, 2024 Helen Knight, director of medicines evaluation at Nice, said: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' Trials have suggested that the treatment, in combination with bortezomib and dexamethasone, delayed progression of the disease by an average of three years, compared to just over a year for patients taking commonly-used drug daratumumab along with the other treatments. Patient Paul Silvester, 60, from Sheffield, was diagnosed with myeloma in July 2023 and received treatment at the Royal Hallamshire Hospital. The first treatment he was given failed to stop his cancer from progressing so he was given belantamab mafodotin through an early access programme. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. 'It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future. 'I've been feeling well and I'm still quite active – that's what's important in terms of your quality of life. 'One of my daughters is graduating from university in October and it's a goal for me to be there.' Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. 'By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country.'

NHS green lights ‘Trojan horse' treatment that attacks cancer cells from inside
NHS green lights ‘Trojan horse' treatment that attacks cancer cells from inside

The Independent

timean hour ago

  • The Independent

NHS green lights ‘Trojan horse' treatment that attacks cancer cells from inside

Blood cancer patients in England are set to be among the first in the world to access a pioneering "Trojan horse" treatment, health officials have announced. The targeted therapy, belantamab mafodotin, also known as Blenrep, has shown promising results in halting the progression of myeloma for nearly three times as long as current treatments, according to studies. Approximately 1,500 patients annually with multiple myeloma, an incurable bone marrow cancer, are expected to benefit from this new treatment. The National Institute for Health and Care Excellence (Nice) has approved Blenrep, manufactured by GlaxoSmithKline, for use within the NHS. NHS England has confirmed that it will be the first health system worldwide to roll out the treatment. The drug will be available to patients whose cancer has advanced or has not responded to initial treatments. Administered as an infusion every three weeks alongside other cancer drugs, this antibody drug targets and attaches to cancer cells. It has been dubbed a 'Trojan horse' treatment because it works by being taken into a cancer cell, before releasing a high concentration of a lethal molecule to destroy the cell from inside. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' Professor Peter Johnson, NHS England's national clinical director for cancer, said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' Helen Knight, director of medicines evaluation at Nice, said: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' Trials have suggested that the treatment, in combination with bortezomib and dexamethasone, delayed progression of the disease by an average of three years, compared to just over a year for patients taking commonly-used drug daratumumab along with the other treatments. Patient Paul Silvester, 60, from Sheffield, was diagnosed with myeloma in July 2023 and received treatment at the Royal Hallamshire Hospital. The first treatment he was given failed to stop his cancer from progressing so he was given belantamab mafodotin through an early access programme. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. 'It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future. 'I've been feeling well and I'm still quite active – that's what's important in terms of your quality of life. 'One of my daughters is graduating from university in October and it's a goal for me to be there.' Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. 'By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store